Retatrutide is a next generation, once weekly weight loss injection that acts on three hormone pathways at once, which is why it is being called a triple agonist
Jingye Zhou, Eccogene CEO Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline Eccogene, a clinical-stage biotech whose oral GLP-1 drug forms the backbone of AstraZenecas obesity pipeline, is planning an initial public offering on the Hong Kong Sign up to read this article for free
Envo gratuito en pedidos superiores a $2,000 MXN.
Henning Langer, PhD: Yeah, I dont know exactly yet on a molecular level what the GLP-1s are doing to change things
Do not attempt to microdose or alter your prescribed medication regimen without seeking medical advice.
The Phase 2 trial data suggests retatrutide produces greater weight loss than either semaglutide or tirzepatide at comparable timepoints